Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme 3 selected

Guidance programme

Showing 1 to 106 of 106

TitleReference numberPublishedLast updated
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHST32
Epilepsies in children, young people and adultsNG217
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Sebelipase alfa for treating Wolman diseaseHST30
Velmanase alfa for treating alpha-mannosidosisHST29
Birch bark extract for treating epidermolysis bullosaHST28
Afamelanotide for treating erythropoietic protoporphyriaHST27
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
Advocacy services for adults with health and social care needsNG227
Self-harm: assessment, management and preventing recurrenceNG225
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social work with adults experiencing complex needsNG216
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Integrated health and social care for people experiencing homelessnessNG214
Odevixibat for treating progressive familial intrahepatic cholestasisHST17
Givosiran for treating acute hepatic porphyriaHST16
Looked-after children and young peopleNG205
Autism spectrum disorder in adults: diagnosis and managementCG142
Safeguarding adults in care homesNG189
Metreleptin for treating lipodystrophyHST14
Volanesorsen for treating familial chylomicronaemia syndromeHST13
Antenatal and postnatal mental health: clinical management and service guidanceCG192
Supporting adult carersNG150
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2HST12
End of life care for adults: service deliveryNG142
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutationsHST11
Patisiran for treating hereditary transthyretin amyloidosisHST10
Alcohol interventions in secondary and further educationNG135
End of life care for infants, children and young people with life-limiting conditions: planning and managementNG61
Motor neurone disease: assessment and managementNG42
Inotersen for treating hereditary transthyretin amyloidosisHST9
Cerebral palsy in adultsNG119
Decision-making and mental capacityNG108
Preventing suicide in community and custodial settingsNG105
Dementia: assessment, management and support for people living with dementia and their carersNG97
Care and support of people growing older with learning disabilitiesNG96
Learning disabilities and behaviour that challenges: service design and deliveryNG93
People's experience in adult social care services: improving the experience of care and support for people using adult social care servicesNG86
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiencyHST7
Autism spectrum disorder in under 19s: recognition, referral and diagnosisCG128
Cystic fibrosis: diagnosis and managementNG78
Child abuse and neglectNG76
Intermediate care including reablementNG74
Vitamin D: supplement use in specific population groupsPH56
Eliglustat for treating type 1 Gaucher diseaseHST5
Antisocial behaviour and conduct disorders in children and young people: recognition and managementCG158
Managing medicines for adults receiving social care in the communityNG67
Mental health of adults in contact with the criminal justice systemNG66
Migalastat for treating Fabry diseaseHST4
Healthcare-associated infections: prevention and control in primary and community careCG139
Cerebral palsy in under 25s: assessment and managementNG62
Coexisting severe mental illness and substance misuse: community health and social care servicesNG58
Physical health of people in prisonNG57
Psychosis and schizophrenia in children and young people: recognition and managementCG155
Harmful sexual behaviour among children and young peopleNG55
Mental health problems in people with learning disabilities: prevention, assessment and managementNG54
Transition between inpatient mental health settings and community or care home settingsNG53
Oral health for adults in care homesNG48
Controlled drugs: safe use and managementNG46
Community engagement: improving health and wellbeing and reducing health inequalitiesNG44
Transition from children's to adults' services for young people using health or social care servicesNG43
Sunlight exposure: risks and benefitsNG34
Older people: independence and mental wellbeingNG32
Care of dying adults in the last days of lifeNG31
Transition between inpatient hospital settings and community or care home settings for adults with social care needsNG27
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into careNG26
Older people with social care needs and multiple long-term conditionsNG22
Home care: delivering personal care and practical support to older people living in their own homesNG21
Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challengesNG11
Violence and aggression: short-term management in mental health, health and community settingsNG10
Excess winter deaths and illness and the health risks associated with cold homesNG6
Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomesNG5
Eculizumab for treating atypical haemolytic uraemic syndromeHST1
Oral health: local authorities and partnersPH55
Managing medicines in care homesSC1
Domestic violence and abuse: multi-agency workingPH50
Antisocial personality disorder: prevention and managementCG77
Healthcare-associated infections: prevention and controlPH36
Unintentional injuries in the home: interventions for under 15sPH30
Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factorsCG110
Alcohol-use disorders: preventionPH24
Improving outcomes for people with skin tumours including melanomaCSG8
Rehabilitation after critical illness in adultsCG83
Borderline personality disorder: recognition and managementCG78
Mental wellbeing in over 65s: occupational therapy and physical activity interventionsPH16
Drug misuse in over 16s: opioid detoxificationCG52
Drug misuse in over 16s: psychosocial interventionsCG51
Improving outcomes for people with brain and other central nervous system tumoursCSG10
Improving outcomes for people with sarcomaCSG9
Obsessive-compulsive disorder and body dysmorphic disorder: treatmentCG31
Improving outcomes in children and young people with cancerCSG7
Improving outcomes in head and neck cancersCSG6
Improving supportive and palliative care for adults with cancerCSG4
Improving outcomes in urological cancersCSG2
Improving outcomes in breast cancerCSG1

Results per page

  1. 10
  2. 25
  3. 50
  4. All